ArticleJournal of the Canadian Association of Gastroenterology2026
Effectiveness of vedolizumab dose escalation in inflammatory bowel disease in a large-scale, Canadian real-world cohort.
Article in Journal of the Canadian Association of Gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: This study explores the effectiveness of vedolizumab dose escalation among patients with ulcerative colitis or Crohn's disease who experienced a suboptimal or loss of clinical response in a Canadian real-world cohort. Methods: Patients with moderately to severely active ulcerative colitis or Crohn's disease treated with vedolizumab were prospectively followed in a patient support program in Canada from 2015 to 2023. In patients who dose escalated to every 4 weeks from every 8 weeks intravenous maintenance dosing, Harvey-Bradshaw Index and Partial Mayo Scores were assessed 12 and 52 weeks after dose escalation. Clinical remission was defined as Harvey-Bradshaw Index < 5 or Partial Mayo Score < 3. Results: This study included 924 patients with Crohn's disease (45% bio-naïve) and 1816 patients with ulcerative colitis (71% bio-naïve). Of patients with Crohn's disease, 39% bio-naïve and 54% bio-experienced dose-escalated within the first 2 years. Of patients with ulcerative colitis, 39% bio-naïve and 50% bio-experienced dose escalated within the first 2 years. For Crohn's disease patients receiving every 8 weekly intravenous maintenance dosing who were not in clinical remission, 50% bio-naïve and 23% bio-experienced patients were in clinical remission 12 weeks after dose escalation, while for ulcerative colitis, 43% bio-naïve and 35% bio-experienced patients were in clinical remission 12 weeks after dose escalation, which was sustained through 52 weeks. Conclusions: For patients who experienced a suboptimal or loss of clinical response to vedolizumab, this study supports the real-world effectiveness of intravenous vedolizumab dose escalation in improving clinical response and clinical remission rates among patients with ulcerative colitis or Crohn's disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.